Patents Examined by Fozia M Hamud
  • Interleukin-15 antagonist peptide
    Patent number: 7736638
    Abstract: Current invention is related to the molecular pharmacology branch particularly to a peptide belonging to the Interleukin-15 sequence (IL-15) which is able to inhibit IL-15 biological activity, analogues or mimetic of such peptides. In the current invention it is shown that the peptide inhibits both IL-15-induced T cells proliferation upon binding to the IL15 receptor a subunit (IL15R?) and TNF?-mediated apoptosis. Besides, this invention is related to the use of this peptide in the treatment of several pathologies where aberrant IL-15 or IL-15R? expression is associated to the disease progression.
    Type: Grant
    Filed: September 16, 2005
    Date of Patent: June 15, 2010
    Assignee: Centro de Ingenieria Genetica y Biotecnologia
    Inventors: Alicia Santos Savio, Ania Cabrales Rico, Osvaldo Reyes Acosta, Haydee Geronimo Perez, Celia Aurora Arrieta Aguero, Silvio Ernesto Perea Rodriguez
  • Methods and compositions for modulating T helper (T) cell development and function
    Patent number: 7731946
    Abstract: Methods and compositions for modulating T helper (Th) cell development and function using modulators of IL-21, e.g., human IL-21, activity or level.
    Type: Grant
    Filed: November 12, 2007
    Date of Patent: June 8, 2010
    Assignees: Wyeth LLC, The President and Fellows of Harvard College
    Inventors: Michael J. Grusby, Andrea Wurster, Deborah Young, Mary Collins, Matthew Whitters
  • Method of using IL-29 cysteine mutant to treat hepatitis C and hepatitis B
    Patent number: 7727518
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Grant
    Filed: March 6, 2008
    Date of Patent: June 1, 2010
    Assignee: ZymoGenetics, LLC
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • Method and composition for treating immune complex associated disorders
    Patent number: 7709451
    Abstract: The present invention provides methods and compositions for treating immune complex associated diseases (ICAD), such as SLE, rheumatoid arthritis, and hepatitis-C related immune complex disease (e.g., cryoglobulinemia) in a subject having an ICAD or at risk for developing ICAD. The invention is based upon the surprising finding that chromatin-containing immune complexes activate autoreactive B cells and dendritic cells by a dual receptor engagement process which, in both cell types, involves a Toll-like receptor (TLR).
    Type: Grant
    Filed: September 9, 2002
    Date of Patent: May 4, 2010
    Assignees: Trustees of Boston University, Yale University
    Inventors: Ann Marshak-Rothstein, Elizabeth A. Leadbetter, Ian R. Rifkin, Mark J. Shlomchik
  • Antibodies that bind to BGS-4
    Patent number: 7705134
    Abstract: The present invention provides novel polynucleotides encoding BGS-4 polypeptides, fragments and homologues thereof. Also provided are vectors, host cells, antibodies, and recombinant and synthetic methods for producing the polypeptides of the present invention. The invention further relates to diagnostic and therapeutic methods for applying these novel BGS-4 polypeptides to the diagnosis, treatment, and/or prevention of various diseases and/or disorders related to these polypeptides. The invention further relates to screening methods for identifying agonists and antagonists of the polynucleotides and polypeptides of the present invention.
    Type: Grant
    Filed: September 10, 2008
    Date of Patent: April 27, 2010
    Assignee: Bristol-Myers Squibb Company
    Inventors: Shujian Wu, Stanley R. Krystek, Jr., Liana M. Lee, John N. Feder, Janet D. Cheng
  • Methods for the treatment of IL-1? related diseases
    Patent number: 7695718
    Abstract: Disclosed are methods for the treatment and/or prevention of Type 2 diabetes, insulin resistance and disease states and conditions characterized by insulin resistance, obesity, hyperglycemia, hyperinsulinemia and Type 1 diabetes, comprising administering to a subject an effective amount of anti-IL-1? antibody or fragment thereof.
    Type: Grant
    Filed: December 20, 2007
    Date of Patent: April 13, 2010
    Assignee: Xoma Technology Ltd.
    Inventors: Alan M. Solinger, Patrick J. Scannon, Robert J. Bauer
  • Methods of using antibodies to human IL-13bc for inhibiting IL-13 binding
    Patent number: 7674591
    Abstract: Polynucleotides encoding the IL-13 receptor and fragments thereof are disclosed. IL-13 receptor proteins, methods for their production, inhibitors of binding of IL-13 and its receptor and methods for their identification are also disclosed.
    Type: Grant
    Filed: February 27, 2006
    Date of Patent: March 9, 2010
    Assignee: Genetics Institute, LLC
    Inventors: Mary Collins, Debra Donaldson, Lori Fitz, Tamlyn Neben, Matthew Whitters, Clive Wood
  • Human DNAX toll-like receptor 4 proteins, related reagents and methods
    Patent number: 7670603
    Abstract: Nucleic acids encoding mammalian Toll-like receptors (TLRs) have been identified in human cells. Recombinantly produced TLRs are used in the preparation of antibodies that are capable of binding to the TLRs. The antibodies are advantageously used in the prevention and treatment of septic shock, inflammatory conditions, and viral infections.
    Type: Grant
    Filed: April 9, 2008
    Date of Patent: March 2, 2010
    Assignee: Schering Corporation
    Inventors: Gerard T. Hardiman, Fernando L. Rock, J. Fernando Bazan, Robert A. Kastelein, Stephen W. K. Ho, Yong-Jun Liu
  • Use of IL-22 for the treatment of conditions of metabolic disorders
    Patent number: 7666402
    Abstract: The use of IL-22 for the treatment of metabolic disorders including hyperlipidemia, obesity, hyperinsulinemia and diabetes. IL-22 may also be used in combination with insulin for diabetes.
    Type: Grant
    Filed: November 16, 2007
    Date of Patent: February 23, 2010
    Assignee: DHY & Co., Ltd.
    Inventors: Yu Liang Huang, Xu Wen Chen
  • Polynucleotide encoding an IL-28A polypeptide
    Patent number: 7662590
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Grant
    Filed: October 19, 2006
    Date of Patent: February 16, 2010
    Assignee: ZymoGenetics, LLC
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • Polynucleotide encoding an IL-28A polypeptide
    Patent number: 7662589
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: February 16, 2010
    Assignee: ZymoGenetics, LLC
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • Methods to increase or decrease bone density
    Patent number: 7655420
    Abstract: The SOST gene gives rise to sclerostin, a protein that leads to apoptosis of bone progenitor cells. The invention provides antagonists to the sclerostin protein, and methods for identifying new sclerostin antagonists. The invention also provides molecules that can depress expression of the SOST gene, as well as methods for identifying such molecules. Such molecules and antagonists are useful for increasing bone mineralization in mammals, for example, in the treatment of osteoporosis.
    Type: Grant
    Filed: December 19, 2007
    Date of Patent: February 2, 2010
    Assignee: Celltech R & D, Inc.
    Inventors: May S. Kung Sutherland, James Charles Geoghegan, John Latham, Changpu Yu
  • Uses of a chemokine receptor able to bind to MCP-1, MIP-1? and/or RANTES
    Patent number: 7655425
    Abstract: A chemokine receptor binds to MCP-1, MIP-1? and/or RANTES. It can be used in screening for agents which act as antagonists to MCP-1, MIP-1? and/or RANTES. Such agents may be useful in treating various disorders, including allergies, atheromas and diseases mediated by viruses. They may also be useful in preventing graft rejection and in protecting stem cells from potentially damaging effects of chemotherapy.
    Type: Grant
    Filed: September 3, 2004
    Date of Patent: February 2, 2010
    Assignee: Glaxo Group Limited
    Inventors: Timothy N. C. Wells, Christine A. Power
  • Stable liquid IL-1 antagonist formulations
    Patent number: 7655758
    Abstract: Formulations of an interleukin-1 (IL-1) antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the IL-1 antagonist is an IL-1 trap composed of a dimer of two fusion proteins having an amino acid sequence of SEQ ID NO: 10. Stable liquid formulations made with and without sodium chloride, and made with phosphate or histidine buffer, are provided.
    Type: Grant
    Filed: March 14, 2008
    Date of Patent: February 2, 2010
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Daniel Dix, Katherine Bowers, Chimanlall Goolcharran, Leu-Fen H. Lin
  • Stimulating neutrophil function to treat inflammatory bowel disease
    Patent number: 7641894
    Abstract: Immune stimulatory amounts of hematopoietic colony stimulating factors are administered to patients with inflammatory bowel disease. The factors include G-CSF and GM-CSF. These factors induce and maintain remission of the disease and its manifestations, whether within the intestine or without.
    Type: Grant
    Filed: April 7, 2006
    Date of Patent: January 5, 2010
    Assignee: Washington University
    Inventors: Brian K. Dieckgraefe, Joshua Korzenik
  • Polynucleotide encoding an IL-28A polypeptide
    Patent number: 7638305
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: December 29, 2009
    Assignee: ZymoGenetics, LLC
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • Use of IL-1 antagonists to treat gout
    Patent number: 7632490
    Abstract: Methods of treating, inhibiting, or ameliorating gout, including chronic acute (refractory) gout, pseudogout, or drug-induced gout, in a human subject in need thereof, comprising administering to a subject in need a therapeutic amount of an interleukin 1 (IL-1) antagonist, wherein the incidence of a gout flare is reduced or inhibited.
    Type: Grant
    Filed: August 28, 2008
    Date of Patent: December 15, 2009
    Assignee: Regeneron Pharmaceuticals, Inc.
    Inventors: Catherine Vicary, Scott Mellis
  • Polynucleotide encoding an IL-28A polypepide
    Patent number: 7629149
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: December 8, 2009
    Assignee: ZymoGenetics, LLC
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • Polynucleotide encoding an IL-28B polypeptide
    Patent number: 7629148
    Abstract: Homogeneous preparations of IL-28A, IL-28B, and IL-29 have been produced by mutating one or more of the cysteine residues in the polynucleotide sequences encoding the mature proteins. The cysteine mutant proteins can be shown to either bind to their cognate receptor or exhibit biological activity. One type of biological activity that is shown is an antiviral activity.
    Type: Grant
    Filed: October 18, 2006
    Date of Patent: December 8, 2009
    Assignee: ZymoGenetics, LLC
    Inventors: Lowell J. Brady, Kevin M. Klucher, Chung Chan, Dennis L. Dong, Hong Y. Liu, Paul O. Sheppard, Thomas R. Bukowski
  • IL-receptor like molecules and uses thereof
    Patent number: 7611857
    Abstract: The present invention provides for IL-17 receptor like polypeptides and nucleic acid molecules encoding the same. The invention also provides vectors, host cells, agonists and antagonists (including selective binding agents), and methods for producing IL-17 receptor like polypeptides. Also provided for are methods for treatment, diagnosis, amelioration, or prevention of diseases with IL-17 receptor like polypeptides.
    Type: Grant
    Filed: October 11, 2005
    Date of Patent: November 3, 2009
    Assignee: Amgen Inc.
    Inventors: Eugene Medlock, Richard Yeh, Scott Michael Silbiger, Gary S. Elliott, Hung Q. Nquyen, Shuqian Jing